Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis
08 août 2023 08h30 HE
|
Orchestra BioMed Holdings, Inc.
Virtue® Sirolimus AngioInfusion Balloon (“SAB”) is the only non-coated angioplasty system providing protected delivery of extended release sirolimus under clinical investigation worldwideVirtue ISR-US...
Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes
26 juin 2023 08h00 HE
|
Orchestra BioMed Holdings, Inc.
NEW HOPE, Pa., June 26, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to...
Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer
07 juin 2023 08h30 HE
|
Orchestra BioMed Holdings, Inc.
Bill Little, previously Chief Operating Officer (COO) of Neovasc, Inc. through its acquisition by Shockwave Medical in April 2023, will lead efforts to forge further strategic collaborations in newly...
Orchestra BioMed to Present at the Jefferies Global Healthcare Conference
01 juin 2023 08h00 HE
|
Orchestra BioMed Holdings, Inc.
NEW HOPE, Pa., June 01, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to...
Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update
12 mai 2023 09h15 HE
|
Orchestra BioMed Holdings, Inc.
Completed business combination and listing on Nasdaq generating gross proceeds of approximately $70 millionBackBeat CNT™ global pivotal study in hypertensive pacemaker patients on track for initiation...
Orchestra BioMed to Present at Upcoming Investor Conferences
07 mars 2023 08h00 HE
|
Orchestra BioMed Holdings, Inc.
NEW HOPE, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to...
Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT™ and Virtue® SAB at CRT 2023
24 févr. 2023 08h00 HE
|
Orchestra BioMed Holdings, Inc.
NEW HOPE, Pa., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to...
Orchestra BioMed Strengthens Senior Leadership Team
07 févr. 2023 08h00 HE
|
Orchestra BioMed Holdings, Inc.
Avi Fischer, M.D., joins as SVP, Medical Affairs and Innovation; J.C. Simeon assumes role of SVP, Quality George Papandreou, Ph.D., promoted to General Manager and SVP, Focal Therapies; Kunal Faldu...
Orchestra BioMed Debuts as Nasdaq-Traded Company with Lead Programs Targeting Hypertension and Artery Disease and Novel Partnership-Enabled Business Model
27 janv. 2023 08h00 HE
|
Orchestra BioMed, Inc.
Business combination with Health Sciences Acquisitions Corporation 2, a special purpose acquisition company sponsored by an affiliate of RTW Investments, LP, completed on January 26, 2023 The...